Lumanity Reorganizes and Expands Strategic Consulting Capabilities
Realigning global, clinical, regulatory, medical, and commercial consulting expertise to facilitate life science clients’ complex commercialization journey
Boston, MA., January 22, 2024 – Lumanity, a global strategic services partner, is realigning its strategic consulting capabilities to help clients more effectively create and demonstrate the value of assets throughout the development and commercialization lifecycle.
Lumanity acquired Clarion, a Boston-based life science consultancy, in October 2022. Clarion is now rebranding under Lumanity. In addition, Lumanity is realigning its Commercial, Medical Affairs, and Clinical and Regulatory Strategy teams into a single global Strategy Consulting capability.
Lumanity’s Strategy Consulting team helps clients identify and create value inflection points for their assets and organizations throughout the product lifecycle. These inflection points occur at critical investment and execution milestones that ultimately determine the success of a product in the marketplace. The creation of this new Strategy Consulting team best leverages Lumanity’s unique and diverse set of deeply experienced strategists, data luminaries, subject matter experts, and proven problem solvers.
“For our clients to navigate the journey from discovery to patient they must facilitate the alignment and exchange of expertise across a broad set of cross-functional experts,” said Jon Williams, the CEO of Lumanity. “When we bring unique combinations of our cross-functional experts together, we can partner with our clients to help bring their own teams closer together, resulting in better decision making and innovative, best-fit solutions with far greater impact.”
The Strategy Consulting team regularly draws on Lumanity’s broader capabilities and expertise in the areas of value demonstration, health economics and outcomes research (HEOR), market access, medical communications, insight, and real-world evidence to assemble and deploy solutions that support the strategic visions of client assets and help demonstrate the value created for all stakeholders.
“Successful value creation for today’s complex assets requires assessment of multiple indication choices, alternative development paths, asset profiles, and clearly defined data requirements often demanded by a broad and global set of clinical, payer, and patient stakeholders. By re-aligning our Strategy Consulting teams under common leadership, we are able to leverage the essential expertise to deliver powerful insights regarding how best to shape each asset and organization for success in the markets of tomorrow,” stated Tom Murtagh, co-founder of Clarion and Joint Global President of Strategy Consulting of Lumanity.
Lumanity’s Strategy Consulting team now consists of over 250 consultants based in the US, UK, and EU. For more information on Lumanity’s strategic consulting capabilities, visit its website.
ENDS
About Lumanity
Lumanity is a global strategic services partner built to effectively blend deep scientific, clinical, medical, regulatory, and commercial expertise to support complex client decision-making and execution throughout the asset value creation and demonstration journey. Lumanity powers successful commercialization and empowers patients, providers, payers, and regulators to take timely and decisive action to accelerate and optimize access to medical advances. With offices in North America, the United Kingdom, Europe, and Asia, and work conducted in over 50 countries, its 1,100+ experts work with nearly all the top pharmaceutical and more than 100 biotech companies around the world. Turning aspiration into reality, Lumanity supports over 50 payer submissions across 20+ countries, launch readiness and commercialization of 80 brands and new indications, and numerous award-winning product campaigns every year. For more information, please visit lumanity.com and connect with Lumanity on Twitter and LinkedIn
CONTACT for Lumanity:
Peter Marangos
+1 702 776 0985 / peter.marangos@lumanity.com
-
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cVANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a di2024-06-17
-
Indonesia Stock Exchange Partners with Nasdaq to Upgrade Market InfrastructureTechnology partnership will further enhance overall resilience and integrity of the exchange, while supporting the rapid deployment of new products2024-06-17
-
Adalvo 的 Liraglutide 預充式注射筆成為歐盟首款獲得批准的仿製藥馬爾他聖瓜安, June 17, 2024 (GLOBE NEWSWIRE) -- Adalvo 宣布 Liraglutide 預充式注射筆成功取得 DCP 批准,成為歐盟首款獲得批准的仿製藥。 根據 IQVIA 的報2024-06-17
-
促进生育,助力三胎——“三胎免费生”联合公益行动正式启动为积极响应国家号召实施三胎生育政策,扩大妇幼服务健康供给,在云南省优生优育妇幼保健协会指导下,昆明广播电视台联合昆明安琪儿妇产医院,于6月13日在昆明广播2024-06-17
-
学党史传承红色精神 守党纪筑牢自律防线——平安养老险湖南分公司党支部开展主题党日活动七一前夕,平安养老险湖南分公司党支部全体成员走进“千年学府、百年师范”——湖南第一师范,开展了一次学史明理、学史增信、学史崇德、学史力行的主题党日活动。重2024-06-17